Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CarPAs: Ponatinib in CML
NCT04709731Phase 2Unknown
- Sponsor
- Associazione Italiana Pazienti Leucemia Mieloide Cronica
- Start
- Feb 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in chronic myeloid leukemia (CML), sponsored by Associazione Italiana Pazienti Leucemia Mieloide Cronica. Status: unknown.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04709731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04709731.